Accessibility Menu

Is Sanofi's Dividend Safe?

The threat of patent expiration on Lantus and competing diabetes drugs from Eli Lilly (LLY) and Novo Nordisk (NVO) could weigh on Sanofi's (SNY) dividend.

By Todd Campbell Jun 23, 2014 at 6:00PM EST

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.